FDA-cleared profile

Volpara Imaging Software

Matakina Technology LTD · Mammography/DBT · FDA-cleared (510(k))

Authorized purpose: Volpara processes raw data from digital breast x-ray systems, including tomosynthesis, to calculate density maps, volumetric breast density, and BI-RADS breast-density categories as adjunctive information for an MQSA-qualified interpreting physician.

Clinical role
Adjunctive breast-density calculation and display for physician interpretation.
Images and patients
Mammography/DBT · Breast
Key limitation
Keep in mind: The software is adjunctive and not interpretive or diagnostic. The MQSA-qualified interpreting physician remains responsible for the final breast-density category and clinical interpretation; compatible raw data and acquisition limits apply.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Volpara processes raw data from digital breast x-ray systems, including tomosynthesis, to calculate density maps, volumetric breast density, and BI-RADS breast-density categories as adjunctive information for an MQSA-qualified interpreting physician.
  • Which images or clinical context are in scope?Modality: Mammography/DBT Anatomy or clinical context: Breast Input: Raw data from compatible digital breast x-ray systems, including digital breast tomosynthesis.
  • Who uses it?Intended users: MQSA-qualified interpreting physicians and trained breast-imaging professionals.
  • What does the software produce?Output: Breast-density maps, quantitative fibroglandular and total-breast volume values, volumetric density ratios, and BI-RADS density categories for review.
  • What is its most important limitation?Key limitation: The software is adjunctive and not interpretive or diagnostic. The MQSA-qualified interpreting physician remains responsible for the final breast-density category and clinical interpretation; compatible raw data and acquisition limits apply.

Clinical takeaway. Clinical role: Volpara processes raw data from digital breast x-ray systems, including tomosynthesis, to calculate density maps, volumetric breast density, and BI-RADS breast-density categories as adjunctive information for an MQSA-qualified interpreting physician.

Evidence takeaway. Evidence from the reviewed source record: The FDA package documents density-map calculations and breast-density categorization from raw digital breast x-ray data; no exact-version independent clinical-outcome evidence was promoted.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Volpara processes raw data from digital breast x-ray systems, including tomosynthesis, to calculate density maps, volumetric breast density, and BI-RADS breast-density categories as adjunctive information for an MQSA-qualified interpreting physician.
  • Exact FDA submission
  • Checked 2026-09-04
Workflow role
Adjunctive breast-density calculation and display for physician interpretation.
  • Exact FDA submission
  • Checked 2026-09-04
Required input
Raw data from compatible digital breast x-ray systems, including digital breast tomosynthesis.
  • Exact FDA submission
  • Checked 2026-09-04
Output and clinician action
Breast-density maps, quantitative fibroglandular and total-breast volume values, volumetric density ratios, and BI-RADS density categories for review.
  • Exact FDA submission
  • Checked 2026-09-04
Care setting
Breast-imaging services using compatible digital mammography or digital breast-tomosynthesis systems.
  • Exact FDA submission
  • Checked 2026-09-04
Intended users
MQSA-qualified interpreting physicians and trained breast-imaging professionals.
  • Exact FDA submission
  • Checked 2026-09-04
Limitations
The software is adjunctive and not interpretive or diagnostic. The MQSA-qualified interpreting physician remains responsible for the final breast-density category and clinical interpretation; compatible raw data and acquisition limits apply.
  • Exact FDA submission
  • Checked 2026-09-04
Evidence summary
The FDA package documents density-map calculations and breast-density categorization from raw digital breast x-ray data; no exact-version independent clinical-outcome evidence was promoted.
  • Exact FDA submission
  • Checked 2026-09-04

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
The FDA package documents density-map calculations and breast-density categorization from raw digital breast x-ray data; no exact-version independent clinical-outcome evidence was promoted.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Reported sensitivity
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-04

No single product-level sensitivity value was promoted because the reviewed FDA material is workflow, module, sequence, or population specific.

Reported specificity
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-04

No single product-level specificity value was promoted because the reviewed FDA material is workflow, module, sequence, or population specific.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

K153427 FDA evidence package for Volpara Imaging Software

  • DesignFDA 510(k) verification and validation evidence described in the exact submission
  • PopulationBreast
  • Scopeexact submission
  • Tested versionVolpara Imaging Software 1.5.2
  • IndependenceSponsor or vendor study

K153427

Manufacturer evidence submitted for the exact FDA decision. It is not independent clinical validation, and local technical, clinical, privacy, security, and workflow acceptance remains necessary.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no candidate record for K153427; no exact native submission identifier match was found.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-04
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

Reimbursement
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging or clinical service line and verify payer, site-of-service, coding, and coverage assumptions independently.
  • Service-level, not product-specific
  • Checked 2026-09-04

No product-specific code

No separate named-product payment identified in reviewed CMS material

Centers for Medicare & Medicaid Services · United States

This is not a product-specific reimbursement determination. Verify payer, site-of-service, coding, and coverage assumptions independently.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Raw data from compatible digital breast x-ray systems, including digital breast tomosynthesis.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-04 · FDA 510(k) decision material K153427: Volpara Imaging Software

  2. Routing

    Source context, not route validation: The exact FDA package describes Volpara using raw data from digital breast x-ray systems, including tomosynthesis, and providing an image output of the density map in DICOM SCI format for visualization. Interface versions and local compatibility require confirmation.

    Scope: Exact FDA submission. Packet wording: "Volpara is a software application intended for use with the raw data from digital breast x-ray systems, including tomosynthesis." … "Image Output None Density map in DICOM SCI format, for visualization as user requires.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-11-14 · FDA 510(k) decision material K153427: Volpara Imaging Software

  3. AI processing

    Source context, not route validation: The exact FDA package describes Volpara operating on a Windows server that meets Volpara data input and output requirements and is generally located outside the patient environment. Current hosting, data flow, and commercial configuration require vendor confirmation.

    Scope: Exact FDA submission. Packet wording: "Volpara operates on a Windows server that meets Volpara data input and output requirements and generally is located outside the patient environment.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-11-14 · FDA 510(k) decision material K153427: Volpara Imaging Software

  4. Returned objects

    Source context, not route validation: Breast-density maps, quantitative fibroglandular and total-breast volume values, volumetric density ratios, and BI-RADS density categories for review.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-04 · FDA 510(k) decision material K153427: Volpara Imaging Software

  5. Viewer/worklist/report

    Unresolved route: Breast-density maps, quantitative fibroglandular and total-breast volume values, volumetric density ratios, and BI-RADS density categories for review.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-04 · FDA 510(k) decision material K153427: Volpara Imaging Software

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The exact FDA package describes Volpara operating on a Windows server that meets Volpara data input and output requirements and is generally located outside the patient environment. Current hosting, data flow, and commercial configuration require vendor confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Volpara operates on a Windows server that meets Volpara data input and output requirements and generally is located outside the patient environment.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

Integration
The exact FDA package describes Volpara using raw data from digital breast x-ray systems, including tomosynthesis, and providing an image output of the density map in DICOM SCI format for visualization. Interface versions and local compatibility require confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Volpara is a software application intended for use with the raw data from digital breast x-ray systems, including tomosynthesis." … "Image Output None Density map in DICOM SCI format, for visualization as user requires.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

Training
Only mqsa-qualified interpreting physicians and trained breast-imaging professionals. should operate or interpret this product. Local onboarding must cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
  • Exact FDA submission
  • Checked 2026-09-04
Monitoring
Monitor K153427 by exact software, hardware, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: The software is adjunctive and not interpretive or diagnostic. The MQSA-qualified interpreting physician remains responsible for the final breast-density category and clinical interpretation; compatible raw data and acquisition limits apply.
  • Exact FDA submission
  • Checked 2026-09-04

Release and scope verification

Map the installed product, build, options, population, anatomy, inputs, outputs, and enabled functions to K153427 before acceptance.

exact submission · checked 2026-09-04

Later product-family features are not evidence that this cleared release includes them.

Deployment boundary

The exact installed deployment, hosting, service, security, and operational boundary remains unverified and requires site-specific confirmation.

exact submission · checked 2026-09-04

FDA-described deployment details do not establish current hosting contracts, security controls, uptime, or local qualification.

Interoperability acceptance

The exact local interoperability contract remains unverified; test supported inputs, outputs, identifiers, routing, archive behavior, and failure handling locally.

exact submission · checked 2026-09-04

Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.

Clinical acceptance

Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. The software is adjunctive and not interpretive or diagnostic. The MQSA-qualified interpreting physician remains responsible for the final breast-density category and clinical interpretation; compatible raw data and acquisition limits apply.

exact submission · checked 2026-09-04

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, infrastructure, training, service, downtime, upgrade, and replacement costs.

product family · checked 2026-09-04

No exact-product price or product-specific reimbursement was established in the reviewed public material.

Lifecycle monitoring

Monitor K153427 by exact software, hardware, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: The software is adjunctive and not interpretive or diagnostic. The MQSA-qualified interpreting physician remains responsible for the final breast-density category and clinical interpretation; compatible raw data and acquisition limits apply.

exact submission · checked 2026-09-04

Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K153427
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
Mammography/DBT
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Anatomy
Breast
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2016-01-07
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-04Last searched
25Fields reviewed
11Source classes checked
3Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

Screened three PubMed titles. They concern volumetric mammographic density but do not identify Volpara Imaging Software 1.5.2 or K153427, so all three are quarantined. The current discovery snapshot contains 3 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, fda decision material, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission

    No public list price for the exact cleared product version was established. Obtain a written quote separating license, implementation, interfaces, compute, storage, training, support, upgrades, renewal, and exit costs.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not publicly available - checked 2026-09-04 - Exact FDA submission

    The FDA decision material does not establish the complete security posture for the exact product and deployment. Obtain architecture, identity, audit, encryption, retention, support-access, vulnerability-management, and incident-response evidence.

  • Installation timeline: Not yet reviewed

7 sources - 3 history items

Source ledger

  1. FDA 510(k) decision material K153427: Volpara Imaging Software

    U.S. Food and Drug Administration - Published 2016-01-07 - Accessed 2026-09-04

    Scope: identity, purpose, clinicalUse, modality, anatomy, intendedUsers, careSetting, workflowRole, input, output, limitations, evidenceSummary

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. Volpara Imaging Software model card (K153427)

    American College of Radiology - Published 2026-06-26 - Accessed 2026-09-01

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. Medicare Coverage Database

    Centers for Medicare & Medicaid Services - Accessed 2026-09-01

    Scope: coverage, codingContext

  7. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

Research history

  1. K153427 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K260714

MammoScreen® (5)

Therapixel

Authorized purpose: Flags calcifications, masses, asymmetries and architectural distortions on compatible FFDM or DBT screening examinations; management must not be based solely on MammoScreen output.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2026-06-26
FDA-cleared K253825

Saige-Dx

DeepHealth, Inc.

Authorized purpose: Concurrent detection and characterization support for screening DBT mammography

Modality
Mammography/DBT
Anatomy
Breast
Decision
2026-06-15
FDA-cleared K252954

MammoSightAI

Neurocareai, Inc. (Dba Savelife.Ai)

Authorized purpose: Tags screening cases as suspicious or blank to aid worklist prioritization; radiologists must review every examination and it does not mark original images.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2026-05-04
FDA-cleared K260320

Lunit INSIGHT MMG (v1.1.10)

Lunit, Inc.

Authorized purpose: Lunit INSIGHT MMG v1.1.10 aids physicians in detection, localization and characterization of suspicious breast-cancer areas on female screening mammograms from compatible FFDM systems, viewed after the physician's initial read as an adjunct to complete clinical interpretation.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2026-04-23

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history